Destiny Pharma PLC XF Drug platform data presented at EuroBiofilms
September 02 2019 - 2:00AM
RNS Non-Regulatory
TIDMDEST
Destiny Pharma PLC
02 September 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma XF Drug platform data to be presented at
EuroBiofilms
Data part of collaboration with Cardiff University to identify
safe and efficacious compounds with a reduced anti-microbial
resistance profile
Brighton, United Kingdom - 2 September 2019 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs which address the global
problem of anti-microbial resistance (AMR), announces that data
from its collaboration, 'Evaluation of XF Drugs as Antibiotic
Resistance Breakers', with Cardiff University is being presented at
the EuroBiofilms conference, in Glasgow, 3-6 September 2019.
The poster, entitled 'Evaluation of the novel XF Drugs: Potent
antibacterial drugs with Twin Mechanisms of Action', is being
presented by Dr Emma Board-Davies, Post-Doctoral Research
Associate, School of Pharmacy and Pharmaceutical Sciences, Cardiff
University. The data looks at the potency of Destiny Pharma's
product platform, including XF-73, XF-70 and DPD-207, against a
range of the critical, infection causing bacteria.
The research programme, 'Evaluation of XF Drugs as Antibiotic
Resistance Breakers,' is a two-year project examining the use of
the Company's novel XF drugs to prevent, control and eradicate life
threatening bacteria or "superbugs" without generating resistance.
It is funded by the UK-China AMR grant fund set up by Innovate UK
and the Department of Health and Social Care with the Chinese
Ministry of Science and Technology at the beginning of 2019.
About EuroBiofilms
EuroBiofilms provides participants with a valuable forum for a
fruitful scientific exchange in the field of microbial biofilms. An
opportunity for scientists, clinicians and industry partners with
an interest in biofilm-related problems to exchange novel
information on clinical, environmental and basic elements of
microbial biofilms.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
from its XF Platform that represent a new approach to the treatment
of infectious disease. The company's lead programme is undergoing a
Phase 2b clinical trial and is targeting the prevention of
post-surgical hospital infections including MRSA. The XF drug
candidates are being developed for the prevention and treatment of
life-threatening infections caused by antibiotic--resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the World
Health Organisation (WHO) and the United Nations, as well as the G7
and the G20 countries. For further information, please visit
www.destinypharma.com
About XF-73
XF-73 is a synthetic anti-microbial active against all tested
Staphylococcus aureus strains, including drug--resistant strains.
By acting via a cell-surface mechanism it affects the bacterial
membrane permeability and integrity, leading to cell death. XF-73
has already been through seven successful Phase I/II clinical
trials showing it is safe and delivers a rapid antibacterial
action. In standard microbiology studies XF drugs have demonstrated
a unique no/low resistance profile that means that XF compounds
have the potential to deliver novel drugs that are clearly
differentiated from traditional antibiotics where resistance limits
their utility.
XF-73 is being studies for the prevention of post-surgical
staphylococcal infections. In the US, there are approximately 40
million surgeries per annum alone where the patient is at risk of a
post-surgical infection. However, within this large population
there are particular groups who are at an even higher risk of
infection due to the nature of their surgery or the procedures
and/or their specific hospital environment in which they are
treated. These higher risk surgical procedures include
cardiovascular, orthopaedic and other complex surgeries. Destiny
Pharma estimates that this totals approximately 14 million US
surgeries per year, with this figure set to rise within the context
of an ageing population.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFFLLBKKFLBBL
(END) Dow Jones Newswires
September 02, 2019 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2023 to Apr 2024